1. Home
  2. FAF vs IBRX Comparison

FAF vs IBRX Comparison

Compare FAF & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First American Corporation (New)

FAF

First American Corporation (New)

HOLD

Current Price

$70.35

Market Cap

6.3B

Sector

Finance

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$10.39

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FAF
IBRX
Founded
1889
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.1B
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
FAF
IBRX
Price
$70.35
$10.39
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$77.67
$12.60
AVG Volume (30 Days)
1.0M
31.1M
Earning Date
05-14-2026
05-18-2026
Dividend Yield
3.14%
N/A
EPS Growth
376.19
38.71
EPS
6.00
N/A
Revenue
$7,452,200,000.00
$113,288,000.00
Revenue This Year
$6.36
$93.25
Revenue Next Year
$5.22
$149.39
P/E Ratio
$11.70
N/A
Revenue Growth
21.61
668.31
52 Week Low
$53.95
$1.83
52 Week High
$70.27
$12.43

Technical Indicators

Market Signals
Indicator
FAF
IBRX
Relative Strength Index (RSI) 66.29 68.35
Support Level $64.27 $2.23
Resistance Level N/A N/A
Average True Range (ATR) 1.98 1.29
MACD 0.28 0.16
Stochastic Oscillator 85.73 68.08

Price Performance

Historical Comparison
FAF
IBRX

About FAF First American Corporation (New)

First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: